Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some high-level mechanistic and general PKU/BH4 responsiveness statements align with the labeled concept of BH4-responsive PKU and use to reduce blood Phe, but several specific quantitative, predictive, and genetic/variant-based claims are not supported by the provided label excerpts and are therefore unsupported.
Category Scores
Accurate Statements
Sapropterin is a synthetic form of tetrahydrobiopterin (BH4).
Not directly supported by the provided excerpts.
Sapropterin helps some newborns with phenylketonuria (PKU) process phenylalanine.
Supported in part by labeled indication to reduce blood Phe levels in patients with BH4-responsive PKU, including pediatric patients one month of age and older; provided excerpts do not support 'newborns' specifically beyond 1 month of age.
Sapropterin works by activating residual phenylalanine hydroxylase (PAH) enzyme activity in patients who respond to BH4.
Conceptually consistent with 'BH4-responsive PKU' but not directly described in the provided excerpts.
Sapropterin increases co-factor availability for the PAH enzyme.
Not directly supported by the provided excerpts.
Sapropterin does not work for classical PKU cases caused by two severe PAH mutations.
Not supported by the provided excerpts.
Unsupported Statements
Only about 20–30% of PKU patients respond to sapropterin.
No response-rate percentage is provided in the supplied label excerpts.
Responders show a 20–30% drop in blood phenylalanine levels after a short BH4 loading test.
No 'loading test' results or 20–30% magnitude/timeframe are provided in the supplied label excerpts.
Genetic testing can predict response to sapropterin based on residual PAH activity.
Label excerpt states biochemical response generally cannot be pre-determined by laboratory testing (e.g., molecular testing) and should be determined via a therapeutic trial; no predictive genetic rule is supported.
When applied early in life, sapropterin often allows reduced dietary phenylalanine restrictions while maintaining safe blood levels.
The excerpts provided do not describe diet restriction reduction or 'safe blood levels' outcomes/claims.
Sapropterin use early in life can reduce the strictness of the special formula diet required for non-responders.
No label excerpt provided supports reduced formula strictness for non-responders.
Sapropterin does not work for classical PKU cases caused by two severe PAH mutations.
No label excerpt provided describes effectiveness by PAH mutation pattern or specifically 'classical PKU due to two severe PAH mutations.'
Patients with classical PKU due to two severe PAH mutations must rely on protein-restricted diets and formula.
No such mutation-specific diet/formula requirement is provided in the supplied excerpts. The excerpts only generally require use with a Phe-restricted diet.
Sapropterin is a synthetic form of tetrahydrobiopterin (BH4).
The provided excerpts refer to BH4-responsive PKU but do not explicitly state that sapropterin is a synthetic form of BH4.
Sapropterin works by activating residual phenylalanine hydroxylase (PAH) enzyme activity in patients who respond to BH4.
The provided excerpts do not describe the mechanism as activating residual PAH activity.
Sapropterin increases co-factor availability for the PAH enzyme.
The provided excerpts do not describe co-factor availability as a mechanism.
Contradictions
High
AI Statement
Genetic testing can predict response to sapropterin based on residual PAH activity.
Label Reference
5.5 Lack of Biochemical Response to JAVYGTOR: 'Biochemical response to JAVYGTOR treatment cannot generally be pre-determined by laboratory testing (e.g., molecular testing), and should be determined through a therapeutic trial (evaluation)....'
Important Omissions
Use with a Phe-restricted diet for all patients treated with JAVYGTOR.
Importance:
High
Evaluation period approach and discontinuation guidance for lack of biochemical response after 1 month at 20 mg/kg/day (i.e., do not continue without response).
Importance:
Moderate
Monitoring blood Phe levels and the risks of prolonged high Phe (severe neurologic damage) and overly low Phe (catabolism/endogenous protein breakdown with adverse developmental outcomes).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Key safety-relevant label requirements (concurrent Phe-restricted diet and blood Phe monitoring) are omitted from the claims. Additionally, the genetic testing predictability claim conflicts with label guidance that response generally cannot be pre-determined by molecular testing and should be determined via a therapeutic trial.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several specific quantitative/statistical, genetic-predictive, mutation-specific, and diet-restriction-reduction claims are unsupported by the provided label excerpts; one claim directly contradicts label text on lack of pre-determination by laboratory (molecular) testing.
Suggested Improvement
Limit statements to what the label excerpts support: indication for BH4-responsive PKU with concurrent Phe-restricted diet and therapeutic-trial-based assessment of biochemical response, plus emphasize monitoring of blood Phe. Remove mutation-specific and percentage/loading-test predictive claims unless supported by additional label text.